research Impact of Pediatric Alopecia Areata on Quality of Life of Patients and Their Family Members: A Nationwide Multicenter Questionnaire Study
Severe pediatric alopecia areata worsens quality of life for patients and families.
Search
for
Sort by
Research
240-270 / 1000+ results 
research 24 ARQ-234: a high affinity CD200-Fc fusion protein for the treatment of atopic dermatitis
ARQ-234, a protein designed to treat atopic dermatitis, shows increased effectiveness in early testing.
research Long-Term Efficacy of Ritlecitinib up to Month 24 From the ALLEGRO Phase 2b/3 and Long-Term Phase 3 Clinical Studies in Alopecia Areata
Ritlecitinib is effective for long-term treatment of severe alopecia areata.
research The type of androgenetic alopecia and quality of life (QoL) in male patients
More severe hair loss worsens quality of life in men.
research Alopecia areata and health-related quality of life: a systematic review and meta-analysis
Alopecia areata significantly lowers the quality of life, especially in emotional and mental health aspects.
research SOVEREIGN PROJECT RE-GENESIS: CONTINUOUS-WAVE PHONOPHORETIC QUANTUM-VOLUMETRIC REGENERATION SYSTEM (CQ-VRS)
research SOVEREIGN PROJECT RE-GENESIS: CONTINUOUS-WAVE PHONOPHORETIC QUANTUM-VOLUMETRIC REGENERATION SYSTEM (CQ-VRS)
research Quality of life assessment using dermatology life quality index questionnaire in patients with alopecia attending a tertiary care teaching hospital: A prospective observational study
Most adults with alopecia have some quality of life impairment, mainly minimal to moderate, and are treated with minoxidil.
research Patient-Reported Satisfaction with Hair Regrowth in a Study of Ritlecitinib in Alopecia Areata: Results from ALLEGRO-2b/3
Ritlecitinib improves hair regrowth satisfaction in alopecia areata patients.
research Androgenetic Alopecia in Al-Qalyubia Governorate: A Comprehensive Review
Current treatments for androgenetic alopecia manage symptoms but don't cure it, and it affects social and psychological well-being.
research The Relationship of Treatment Modality in Alopecia Areata with Life Quality, Anxiety, and Depression
Alopecia areata treatment should consider life quality and mental health, not just clinical results.
research Identification and characterization of alopecia areata subgroups regarding quality of life impairment based on demographic, clinical, psychological, and social factors
Psychological therapies may improve quality of life for people with alopecia areata.
research [Androgenetic alopecia and quality of life].
research Distribution of SALT scores by Therapeutic Tesponse in Patients with Severe Alopecia After 52 weeks of Baricitinib Therapy
Baricitinib therapy helped many patients with severe alopecia regrow hair after 52 weeks.
research Treatment of androgenetic alopecia with 5-aminolevulinic acid photodynamic therapy: A randomized, placebo-controlled, split-scalp study of efficacy and safety
Using 5-aminolevulinic acid photodynamic therapy for hair loss didn't increase hair growth but slightly reduced scalp oiliness, and it was safe with mild side effects.
research The Dermatology Life Quality Index (DLQI ) used as the benchmark in validation of 101 quality‐of‐life instruments: A systematic review
The DLQI is a key tool for measuring quality of life in dermatology.
research SALT score distribution with ritlecitinib treatment up to 24 months in alopecia areata
Ritlecitinib improves hair regrowth in alopecia areata over 24 months.
research USE OF RITLECITINIB FOR THE TREATMENT OF ALOPECIA AREATA
Ritlecitinib effectively treats alopecia areata in patients 12 and older with fewer side effects.
research Quality of Life in Alopecia Areata: A Study of 60 Cases
Alopecia areata seriously lowers quality of life, especially affecting self-image, mental health, and social life.
research Alopecia areata incognita: a comment
The author clarified that Alopecia Areata Incognita (AAI) and diffuse Alopecia Areata (AA) are different conditions and the case discussed was actually AA, not AAI.
research Updated Integrated Safety Analysis of Ritlecitinib up to ~5 Years in Adolescents With Alopecia Areata From the ALLEGRO Clinical Trials
Ritlecitinib is generally safe for adolescents with alopecia areata over 5 years.
research Low quality of life and high HSS‐29 scores reflect the risk of loss to follow‐up: a study in patients with androgenetic alopecia
Low quality of life and high HSS-29 scores increase risk of losing patients during treatment.
research Alopecia associated with quetiapine
Quetiapine may cause hair loss, a side effect not widely recognized before.
research Investigating material basis and molecular mechanism of Qing Cuo formula in the treatment of acne based on animal experiments, UPLC-LTQ-Orbitrap-MS and network pharmacology
Qing Cuo Formula may effectively treat acne by reducing inflammation and hormone levels.
research Comparison of quality of life in patients with androgenetic alopecia and alopecia areata
Both androgenetic alopecia and alopecia areata negatively impact quality of life, with no significant difference between them.
research Rapid and Sensitive LC–MS–MS Method for the Simultaneous Estimation of Alfuzosin and Dutasteride in Human Plasma
A fast and accurate method was developed to measure alfuzosin and dutasteride in human plasma.
research Cost‐Effectiveness Analysis of Ritlecitinib Compared With No Treatment in Patients With Severe Alopecia Areata in Japan
Ritlecitinib is cost-effective for severe alopecia areata in Japan.
research QuantAnts machines discover biomarkers for RAS signaling activation and design sgRNAs for CRISPR to target complex CD9, CD34, and CD74.
The QuantAnts machines can find cancer markers and create CRISPR targets for them.
research Quercetin Nanocrystal Gel: A Novel Topical Therapeutic Strategy for Androgenetic Alopecia
Quercetin nanocrystal gel shows promise for hair regrowth in androgenetic alopecia.
research Long-Term Efficacy and Safety of Ritlecitinib in Adults and Adolescents with Alopecia Areata: 3-Year Results from the ALLEGRO Phase 2b/3 and ALLEGRO-LT Phase 3 Clinical Studies
Ritlecitinib is effective and safe for long-term use in treating severe alopecia areata in people aged 12 and older.